Elicio Therapeutics Inc (ELTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.40-10.26%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ELTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ELTX — earnings miss
Dated 2026-05-11
Results of Operations and Financial Condition. On May 11, 2026 , Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securiti…
Why it matters: The trial tests ELI-002 with a RAS drug, with or without anti-PD-1, in metastatic pancreatic cancer.
Supportive ifElicio announces that the Phase 1 trial has opened by December 31, 2026.
Worry ifElicio reports that the trial has not opened by December 31, 2026, or delays it beyond Q4 2026.
Why it matters: The company reported cash to fund operations into Q1 2027. Its trial plans may depend on added funding.
Worry ifA filing or company update says cash will cover planned operations through Q1 2027 or later. No new funding is needed before then.
Less concerning ifA filing or company update says cash will not cover planned operations through Q1 2027. Or, the company needs new funding before then.
Why it matters: The Phase 2 trial missed its main goal across all patients. The R0 result is post-hoc, so the next trial plan matters.
Supportive ifElicio reports a Phase 3 plan for R0 patients with dosing beyond the earlier booster plan, and gives a start window.
Worry ifElicio reports no Phase 3 plan, drops the R0 focus, or says the trial cannot proceed without funding.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$215 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $974 loss on $10,000 · 9.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,976 loss on $10,000 · 89.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.